Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 11, 2001
Last year, WDI was awarded the tender to supply the Government of South Africa with rapid diagnostic tests to be used in the early detection and curtailment of the spread of HIV/AIDS. The government program has been underway for approximately a year, and the tender was awarded only to WDI and Abbott Diagnostics to work in concert for screening and confirmatory purposes. Since then WDI has increased its product sales to include other infectious disease tests, including drugs of abuse tests. The government program is entirely voluntary. Education and advertising campaigns are utilized to increase the volume of volunteers.
Barry Peters, chairman of WDI, stated, "Private sector testing represents an immediate and important market sector to WDI, since employers maintain the right to screen employees who must comply with healthcare programs aimed at disease identification and containment. WDI's penetration into South Africa's private sector establishes links with such multi-national companies as Nestle, which can be used to expand into other countries where other multi-nationals have concerns relating to employee healthcare.
"Initial product shipments to support private sector testing in South Africa for the quarter ending March 31, 2002 could reach approximately $250,000 in value," Peters concluded.
WDI considers Africa to be its single largest area of demand for its rapid HIV product. Currently, cases of hospital-treated infection are estimated at 18% to 20% of the population, and estimates of the untreated portion of the work force constitute another 20% to 25%.
About World Diagnostics, Inc. and GLOBALeMED.com
World Diagnostics, Inc. is a leading provider of a wide range of medical diagnostic and laboratory products worldwide. The Company offers a simplified way to purchase those products through its GLOBALeMED system, which also provides medical professionals access to critical technical data and information, training aids and online customer support.
The Company's network of distributors and GLOBALeMED partners now covers 84 countries, offering the most comprehensive resource for most medical diagnostic tests and laboratory products, of which about 1,000 are World Diagnostic-branded. Numerous other products are also sold through distributors and directly to medical professionals, hospitals, physician offices, clinical laboratories and retail drug stores. For more information about the Company and its products, visit or http://www.worlddiagnostics.com or http://www.otcfn.com/wdgi.
Contact: World Diagnostics: Barry Peters, Chairman, 310-234-9535, e-mail: bpeters@worlddiagnostics.com; Investor Relations: OTC Financial Network, Rick Iler, 781-444-6100 or 877-882-1640, ext. 648, email: riler@otcfn.com, http://www.otcfn.com/wdgi.
Except for historical matters contained herein, certain matters discussed herein, including references to projected revenues, are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although WDI believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Factors that could cause actual results to differ materially from WDI expectations include changes by prospective purchasers of their business plans or financial condition changes in general economic conditions, competition, changes in technology, our ability to procure products for resale, and other risks detailed from time to time in the WDI reports filed with the Securities and Exchange Commission, including annual reports on Form 10-KSB and quarterly reports on Form 10-QSB.
SOURCE World Diagnostics, Inc. Web Site: http://www.worlddiagnostics.com
011211
PR011216
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .